title: [Correlation between pyrimidine nucleoside phosphorylase (PyNPase)/thymidine phosphorylase/platelet-derived endothelial cell growth factor and histological prognostic factor, and influence of 5'-deoxy-5-fluorouridine (5'-DFUR) administration on PyNPase activities and serum immunosuppressive acidic protein levels. A study group of oral anti-cancer drugs in Seiban/Tajima area].
abstract: OBJECTIVE
  Among the pyrimidine nucleoside phosphorylases (PyNPase), thymidine phosphorylase (dThdPase) exists mainly in human tumor tissues, and is an enzyme which converts 5'-deoxy-5-fluorouridine (5'-DFUR) to 5-fluorouracil. Recently, it was reported that dThdPase was identical to platelet-derived endothelial cell growth factor which was an antiogenetic factor, therefore. We think dThdPase may be a prognostic factor.
  
  
  METHODS
  We investigated the possible correlation between PyNPase activities in tumor tissues and prognostic factors of histological findings, and examined influences of preoperative oral 5'-DFUR administration at a dose of 1,200 mg/body for 7 days on PyNPase activities and serum immunosuppressive acidic protein levels in patients with gastric cancer.
  
  
  RESULTS
  Higher levels of PyNPase activities were especially observed in patients with v+ (p = 0.0161). PyNPase activities (p = 0.1668) and IAP (p = 0.0830) levels showed a decrease by 5'-DFUR administration.
  
  
  CONCLUSIONS
  This study suggests that we must investigate in detail the possibility of PyNPase being prognostic factor, and 5'-DFUR administration may improve the prognosis of patients with gastric cancer.
authors.affiliation: Dept. of Surgery, National Himeji Hospital.
authors.forename: B
authors.initials: B
authors.lastname: Satoh
authors.forename: M
authors.initials: M
authors.lastname: Ohtoshi
authors.forename: Y
authors.initials: Y
authors.lastname: Ishida
authors.forename: K
authors.initials: K
authors.lastname: Hen-mi
authors.forename: I
authors.initials: I
authors.lastname: Kaneko
authors.forename: M
authors.initials: M
authors.lastname: Soda
authors.forename: J
authors.initials: J
authors.lastname: Sugihara
authors.forename: F
authors.initials: F
authors.lastname: Shibagaki
authors.forename: N
authors.initials: N
authors.lastname: Iwai
authors.forename: T
authors.initials: T
authors.lastname: Nakamura
authors.forename: T
authors.initials: T
authors.lastname: Yamasaki
authors.forename: S
authors.initials: S
authors.lastname: Matsumoto
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000097:blood*; D010430:Pentosyltransferases / Q000378:metabolism*; D011379:Prognosis; D057845:Pyrimidine Phosphorylases; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology*; D013939:Thymidine Phosphorylase / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; C030193:immunosuppressive acidic protein; D005467:Floxuridine; D010430:Pentosyltransferases; D057845:Pyrimidine Phosphorylases; D013939:Thymidine Phosphorylase; C025034:doxifluridine